Spyre Therapeutics (SYRE) Change in Acquisitions & Divestments (2016 - 2026)

Spyre Therapeutics (SYRE) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $107.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 50.94% year-over-year to $107.7 million; the trailing twelve-month figure through Mar 2026 stood at $408.1 million (up 51.37% YoY), and the FY2025 full-year result was $371.7 million, up 51.13% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $107.7 million, up from $94.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $107.7 million in Q1 2026 and bottomed at $3.2 million in Q2 2023.
• The 5-year median for Change in Acquisitions & Divestments is $52.8 million (2024), against an average of $53.9 million.
• The widest annual swing landed in 2023, when Change in Acquisitions & Divestments plunged 87.0%; it then soared 1680.8% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $18.5 million in 2022, then grew by 2.16% to $18.9 million in 2023, then surged by 230.94% to $62.5 million in 2024, then surged by 50.76% to $94.3 million in 2025, then advanced by 14.26% to $107.7 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $107.7 million (Q1 2026), $94.3 million (Q4 2025), and $99.2 million (Q3 2025), per Business Quant data.

Peer Comparison